Zika Virus Infection Clinical Trial
Official title:
Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA
The purpose of this study is to evaluate the performance of the ZIKV Detect™ 2.0 IgM Capture ELISA using archived confirmed ZIKV positive and confirmed ZIKV negative human serum samples.
The purpose of this study is to evaluate the performance of the ZIKV Detect™ 2.0 IgM Capture ELISA using archived confirmed ZIKV positive and confirmed ZIKV negative human serum samples. The FDA guidance document (ZIKA SEROLOGY DE NOVO/510(K) PRE-MARKET SUBMISSIONS - Recommended Analytical and Clinical Studies for Zika Virus IgM Assays; Dated 02Jun2017; FDA/CDRH/OIR/DMD) allows for the utilization of archival serum specimens to evaluate test performance. This study will follow this guidance. Test samples will be collected from endemic sites (both presumed positive and presumed negative samples) and from non-endemic sites (presumed negative samples). All samples will be shipped to the sponsor for randomization and will be tested at three sites in the United States. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04697147 -
Zika and Neurodevelopment Among Infants in Grenada
|
N/A | |
| Completed |
NCT03631719 -
Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
|
||
| Completed |
NCT02952833 -
ZIKA Vaccine in Naive Subjects
|
Phase 1 | |
| Terminated |
NCT03055585 -
Applying Wolbachia to Eliminate Dengue
|
N/A | |
| Not yet recruiting |
NCT05589012 -
Evaluation of Viral Replication by Tonate Virus (TONV) and Zika Virus (ZIKV), Within an ex Vivo Trophoblast and Placental Model
|
||
| Completed |
NCT02963909 -
A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.
|
Phase 1 | |
| Completed |
NCT03110770 -
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
|
Phase 2 | |
| Recruiting |
NCT06334393 -
Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
|
Phase 1 | |
| Completed |
NCT03008122 -
Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area
|
Phase 1 | |
| Terminated |
NCT03161444 -
Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection.
|
N/A | |
| Completed |
NCT04478656 -
Safety and Immunogenicity of BBV121
|
Phase 1 | |
| Completed |
NCT03624946 -
Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)
|
Phase 1 | |
| Completed |
NCT03330600 -
Efficacy of Aquatic Physiotherapy in Children With Microcephaly by Zika Virus Congenital Syndrome
|
N/A | |
| Completed |
NCT05041439 -
Adherence to Care for Children With Congenital Zika Virus Infection in Puerto Rico
|
N/A | |
| Recruiting |
NCT03255369 -
Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF)
|
||
| Completed |
NCT03206541 -
Neurologic Manifestations of the Arbovirus Infection in Colombia
|
||
| Completed |
NCT03425149 -
Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults
|
Phase 1 | |
| Completed |
NCT04033068 -
Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001)
|
Phase 1 | |
| Completed |
NCT03679728 -
Sensorimotor Outcomes of Children Exposed to Foetal Zika Virus Infection
|
||
| Withdrawn |
NCT03204409 -
ZIKAlliance Natural History Study
|